These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27856823)

  • 1. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Varricchi G; Bagnasco D; Ferrando M; Puggioni F; Passalacqua G; Canonica GW
    Ther Adv Respir Dis; 2017 Jan; 11(1):40-45. PubMed ID: 27856823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential Mechanisms of Differential Activation of Eosinophils by IL-3 Compared to GM-CSF and IL-5.
    Esnault S; Kelly EA
    Crit Rev Immunol; 2016; 36(5):429-444. PubMed ID: 28605348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
    Dávila González I; Moreno Benítez F; Quirce S
    J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
    Yanagibashi T; Satoh M; Nagai Y; Koike M; Takatsu K
    Cytokine; 2017 Oct; 98():59-70. PubMed ID: 28863833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma.
    Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
    BMC Pulm Med; 2019 Aug; 19(1):158. PubMed ID: 31438916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mepolizumab in the treatment of severe eosinophilic asthma.
    Fainardi V; Pisi G; Chetta A
    Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approaches in the treatment of asthma.
    Ramshaw HS; Woodcock JM; Bagley CJ; McClure BJ; Hercus TR; Lopez AF
    Immunol Cell Biol; 2001 Apr; 79(2):154-9. PubMed ID: 11264710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab for eosinophilic severe asthma: recent studies.
    Robinson DS; Kariyawasam HH
    Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-3 Maintains Activation of the p90S6K/RPS6 Pathway and Increases Translation in Human Eosinophils.
    Esnault S; Kelly EA; Shen ZJ; Johansson MW; Malter JS; Jarjour NN
    J Immunol; 2015 Sep; 195(6):2529-39. PubMed ID: 26276876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative contributions of human types 1 and 2 T-helper cell-derived eosinophilotrophic cytokines to development of eosinophilia.
    Wierenga EA; Backx B; Snoek M; Koenderman L; Kapsenberg ML
    Blood; 1993 Sep; 82(5):1471-9. PubMed ID: 8364199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.
    Panousis C; Dhagat U; Edwards KM; Rayzman V; Hardy MP; Braley H; Gauvreau GM; Hercus TR; Smith S; Sehmi R; McMillan L; Dottore M; McClure BJ; Fabri LJ; Vairo G; Lopez AF; Parker MW; Nash AD; Wilson NJ; Wilson MJ; Owczarek CM
    MAbs; 2016; 8(3):436-53. PubMed ID: 26651396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells.
    Yamada T; Sun Q; Zeibecoglou K; Bungre J; North J; Kay AB; Lopez AF; Robinson DS
    J Allergy Clin Immunol; 1998 May; 101(5):677-82. PubMed ID: 9600506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mepolizumab for the treatment of severe eosinophilic asthma.
    Poulakos MN; Cargill SM; Waineo MF; Wolford AL
    Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
    Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
    Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.
    Luo J; Chen W; Liu W; Jiang S; Ye Y; Shrimanker R; Hynes G; Klenerman P; Pavord ID; Xue L
    Mucosal Immunol; 2024 Aug; 17(4):524-536. PubMed ID: 38493955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed eosinophil apoptosis in asthma.
    Kankaanranta H; Lindsay MA; Giembycz MA; Zhang X; Moilanen E; Barnes PJ
    J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):77-83. PubMed ID: 10887309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood CD4 but not CD8 t-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy.
    Corrigan CJ; Hamid Q; North J; Barkans J; Moqbel R; Durham S; Gemou-Engesaeth V; Kay AB
    Am J Respir Cell Mol Biol; 1995 May; 12(5):567-78. PubMed ID: 7742019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
    Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
    Front Immunol; 2020; 11():593748. PubMed ID: 33488590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.